Mochida Pharmaceutical Co., Ltd. (JP:4534) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mochida Pharmaceutical Co., Ltd. reported a 3.3% increase in net sales for the six months ending September 30, 2024, compared to the same period last year, despite a slight decrease in operating and attributable profits. The company’s equity-to-asset ratio improved to 81.5%, and they maintained their dividend forecast, indicating stable financial performance. Investors may find Mochida’s resilience and consistent dividend policy appealing amidst fluctuating profits.
For further insights into JP:4534 stock, check out TipRanks’ Stock Analysis page.